CNMD
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E of 25.39 is high for current earnings, though Forward P/E of 7.78 suggests expected recovery.
- Low P/S ratio
- P/B ratio near 1.0
- Price exceeds Graham Number
- Price significantly exceeds Intrinsic Value formula
Growth metrics are heavily negative on the bottom line.
- Modest revenue growth (7.9%)
- Earnings growth -50%
- Consistent failure to meet EPS estimates
Long-term trend is aggressively bearish.
- Historical ability to beat estimates prior to 2025
- 5-year return of -70.3%
- 1-year return of -24.3%
The company is financially stable but operationally inefficient.
- Piotroski F-Score 7/9
- Current Ratio 2.14
- Manageable Debt/Equity 0.86
- Low ROE (4.71%)
Dividend is safe but not a primary driver for total return.
- Consistent payout
- Low payout ratio (39.74%)
- Low yield (2.09%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CNMD and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CNMD
CONMED Corporation
Primary
|
-70.3% | -65.8% | -24.3% | -19.7% | +3.4% | -1.9% |
|
EYPT
EyePoint, Inc.
Peer
|
+41.6% | +326.8% | +243.1% | +2.1% | -9.6% | +8.8% |
|
ALVO
Alvotech
Peer
|
-65.9% | -71.8% | -66.2% | -52.0% | -17.7% | -1.6% |
|
SEPN
Septerna, Inc.
Peer
|
+22.1% | +22.1% | +342.9% | +18.4% | +8.4% | +13.2% |
|
IRMD
IRADIMED CORPORATION
Peer
|
+324.4% | +136.8% | +89.2% | +31.5% | -7.3% | -2.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CNMD
CONMED Corporation
|
BEARISH | $1.18B | 25.39 | 4.7% | 3.4% | $38.34 | |
|
EYPT
EyePoint, Inc.
|
NEUTRAL | $1.18B | - | -72.2% | -% | $14.17 | Compare |
|
ALVO
Alvotech
|
BEARISH | $1.19B | 16.61 | -% | 12.1% | $3.82 | Compare |
|
SEPN
Septerna, Inc.
|
NEUTRAL | $1.17B | - | -12.2% | -106.4% | $26.13 | Compare |
|
IRMD
IRADIMED CORPORATION
|
NEUTRAL | $1.19B | 53.37 | 24.8% | 26.8% | $93.4 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | LALOMIA BRENT | Officer | Stock Award | 75 | - |
| 2026-02-24 | KAYE MARK | Director | Stock Award | 152 | - |
| 2025-11-21 | GLAZE RICHARD | Chief Technology Officer | Sale | 257 | $10,591 |
| 2025-11-20 | GLAZE RICHARD | Chief Technology Officer | Stock Award | 375 | - |
| 2025-11-06 | GARNER TODD W. | Chief Financial Officer | Sale | 3,500 | $150,500 |
| 2025-11-04 | FOUST HOLLIE K | General Counsel | Stock Award | 4,000 | - |
| 2025-10-31 | GARNER TODD W. | Chief Financial Officer | Stock Award | 7,500 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
CNMD filed its annual 10-K report on February 17, 2026, which includes standard disclosures regarding its business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.
For the nine months ending September 30, 2025, the Gore® VIABIL® device generated $44.1 million in net sales with a gross profit margin of approximately 38%. A significant upcoming risk is the loss of this revenue stream, as CONMED will not renew its distribution agreement for the device after December 31, 2026. The company reports no material financial impact from geopolitical conflicts in Ukraine and the Middle East.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning CNMD from our newsroom.